NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Eligo Bioscience

Eligo Bioscience

Private
ParisHealthcare & Life Scienceshttps://eligo.bio/

Last Round

Grant

May 13, 2025

Total Funding Raised

$65.34M

Company Overview

Eligo Bioscience is a biotechnology company that develops in vivo gene editing technologies to modulate the microbiome for the treatment of bacteria-associated diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

microbiome therapeuticsCRISPRgene editingprecision medicinegenetic medicinebacterial engineeringdrug discoveryphage therapycomputational biologyin vivo engineeringbiotech platformsynthetic biologymicrobiome modulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eligo Bioscience Comparables

Compare Eligo Bioscience with similar companies based on industry and business-model similarity.

Eligo Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SNIPR Biome
88%
Locus Biosciences
85%
Nemesis Bioscience
83%

Eligo Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 13, 2025
Series BDec 5, 2023
GrantMay 1, 2019
Series ASep 26, 2017
SeedJul 8, 2015

Key People

Founding team and executive leadership

Xavier Duportet

Co-founder CEO

Founding Team

Aurélie Grienenberger

Chief Operating Officer

Executive Team

Eligo Bioscience Investors

Notable investors and investment history

Eligo Bioscience investors
InvestorRounds
Khosla VenturesSeries B, Series A
European CommissionGrant
BpifranceSeries B, Grant
Government of FranceGrant
Sanofi VenturesSeries B
BpifranceGrant
Seventure PartnersSeries A, Series B, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 23, 2025

    Recognized as one of the World Economic Forum’s 30 Most Innovative Companies.

  • May 13, 2025

    Partnered with Biose Industries for microbial fermentation.

Eligo Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eligo Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eligo Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range46
Year Founded2014
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.